Ajanta Pharma is expanding its manufacturing capabilities by adding a state-of-the-art liquid formulation facility at its Pithampur site. This enhancement is aimed at meeting the growing global demand for the company's liquid formulations. The investments required for the capacity addition is Rs 92 crore, which will be financed through internal accruals.
The company’s existing capacity comprises of 6 million Bottles per annum on single shift basis with capacity utilization of 175%. The proposed capacity addition is of 12 million bottles per annum on single shift basis and will be added by Q1 FY 2026.
Ajanta Pharma is a specialty pharmaceuticals formulation company with a well-diversified Branded Generics business spread across India, the rest of Asia, and Africa.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: